Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2014

01-01-2014 | Research Article

Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions

Authors: Constantinos Giaginis, Paraskevi Alexandrou, Ioanna Delladetsima, Ioanna Giannopoulou, Efstratios Patsouris, Stamatios Theocharis

Published in: Tumor Biology | Issue 1/2014

Login to get access

Abstract

Histone deacetylases (HDACs) have been associated with human malignant tumor development and progression, and HDAC inhibitors are currently being explored as anticancer agents in clinical trials. The present study aimed to evaluate the clinical significance of HDAC-1, HDAC-2, HDAC-4, and HDAC-6 proteins' expression in human malignant and benign thyroid lesions. HDAC-1, HDAC-2, HDAC-4, and HDAC-6 proteins' expression was assessed immunohistochemically on paraffin-embedded thyroid tissues obtained from 74 patients with benign and malignant thyroid lesions. Enhanced HDAC-2 and HDAC-6 expression was significantly more frequently observed in malignant, compared to benign, thyroid lesions (p = 0.0042 and p = 0.0069, respectively). Enhanced HDAC-2, HDAC-4, and HDAC-6 expression was significantly more frequently observed in cases with papillary carcinoma compared to hyperplastic nodules (p = 0.0065, p = 0.0394, and p = 0.0061, respectively). In malignant thyroid lesions, HDAC-1, HDAC-4, and HDAC-6 expression was significantly associated with tumor size (p = 0.0169, p = 0.0056, and p = 0.0234, respectively); HDAC-2 expression with lymphatic and vascular invasion (p = 0.0299 and p = 0.0391, respectively); and HDAC-4 expression with capsular invasion (p = 0.0464). The cellular pattern of HDAC-1 and HDAC-2 distribution (nuclear vs. nuclear and cytoplasmic) presented a distinct discrimination between malignant and benign thyroid lesions (p = 0.0030 and p = 0.0028, respectively) as well as between papillary carcinoma and hyperplastic nodules (p = 0.0036 and p = 0.0028, respectively). HDAC-1, HDAC-2, HDAC-4, and HDAC-6 may be associated with the malignant thyroid transformation and could be considered as useful biomarkers and possible therapeutic targets in this neoplasia.
Literature
1.
Leenhardt L, Grosclaude P, Cherie-Challine L. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid. 2004;14:1056–60.PubMedCrossRef
2.
3.
Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–7.PubMedCrossRef
4.
Ward EM, Jemal A, Chen A. Increasing incidence of thyroid cancer: is diagnostic scrutiny the sole explanation? Future Oncol. 2010;6:185–8.PubMedCrossRef
5.
Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer. 1998;83:2638–48.PubMedCrossRef
6.
Segev DL, Umbricht C, Zeiger MA. Molecular pathogenesis of thyroid cancer. Surg Oncol. 2003;12:69–90.PubMedCrossRef
7.
Gharib H, Papini E. Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am. 2007;36:707–35.PubMedCrossRef
8.
Schlumberger M, Lacroix L, Russo D, Filetti S, Bidart JM. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab. 2007;3:260–9.PubMedCrossRef
9.
Stang MT, Carty SE. Recent developments in predicting thyroid malignancy. Curr Opin Oncol. 2009;21:11–7.PubMedCrossRef
10.
Fischer S, Asa L. Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med. 2008;132:359–72.PubMed
11.
Besic N, Sesek M, Peric B, et al. Predictive factors of carcinoma in 327 patients with follicular neoplasm of the thyroid. Med Sci Monit. 2008;14:CR459–67.PubMed
12.
Vriens MR, Schreinemakers JM, Suh I, et al. Diagnostic markers and prognostic factors in thyroid cancer. Future Oncol. 2009;5:1283–93.PubMedCrossRef
13.
Aisner DL, Sams SB. The role of cytology specimens in molecular testing of solid tumors: techniques, limitations, and opportunities. Diagn Cytopathol. 2012;40:511–24.PubMedCrossRef
14.
Morales V, Giamarchi C, Chailleux C, et al. Chromatin structure and dynamics: functional implications. Biochimie. 2001;83:1029–39.PubMedCrossRef
15.
Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194–202.PubMedCrossRef
16.
Grozinger CM, Schreiber SL. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol. 2002;9:3–16.PubMedCrossRef
17.
18.
19.
Kouraklis G, Theocharis S. Histone deacetylase inhibitors: a novel target of anticancer therapy (review). Oncol Rep. 2006;15:489–94.PubMed
20.
Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27:5459–68.PubMedCrossRef
21.
Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–84.PubMedCrossRef
22.
Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs. 2009;69:1911–34.PubMedCrossRef
23.
Molife LR, de Bono JS. Belinostat: clinical applications in solid tumors and lymphoma. Expert Opin Investig Drugs. 2011;20:1723–32.PubMedCrossRef
24.
25.
Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol. 2012;90:85–94.PubMedCrossRef
26.
Halkidou K, Gaughan L, Cook S. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 2004;59:177–89.PubMedCrossRef
27.
Weichert W, Denkert C, Noske A, et al. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia. 2008;10:1021–7.PubMedCentralPubMed
28.
Weichert W, Roske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008;9:139–48.PubMedCrossRef
29.
Weichert W, Roske A, Niesporek S, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008;14:1669–77.PubMedCrossRef
30.
31.
Wang W, Gao J, Man XH, et al. Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer. Oncol Rep. 2009;21:1439–47.PubMed
32.
Rikimaru T, Taketomi A, Yamashita Y, et al. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology. 2007;72:69–74.PubMedCrossRef
33.
Sasaki H, Moriyama S, Nakashima Y, et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer. 2004;46:171–8.PubMedCrossRef
34.
Krusche CA, Wulfing P, Kersting C, et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat. 2005;90:15–23.PubMedCrossRef
35.
Zhang Z, Yamashita H, Toyama T, et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat. 2005;94:11–6.PubMedCrossRef
36.
Marquard L, Gjerdrum LM, Christensen IJ. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology. 2008;53:267–77.PubMedCentralPubMedCrossRef
37.
Marquard L, Poulsen CB, Gjerdrum LM, et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology. 2009;54:688–98.PubMedCrossRef
38.
Oehme I, Deubzer HE, Wegener D, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res. 2009;15:91–9.PubMedCrossRef
39.
Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009;280:168–76.PubMedCrossRef
40.
Rosai J, Appendix C. Staging of cancer. In: Houston M, editor. Rosai and Ackerman's Surgical Pathology. 9th ed. London: Mosby; 2004. p. 2809–10.
41.
Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341.PubMedCrossRef
42.
Theocharis S, Klijanienko J, Giaginis C, et al. Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Oral Pathol Med. 2011;40:706–14.PubMedCrossRef
43.
Michailidi C, Giaginis C, Stolakis V, et al. Evaluation of FAK and Src expression in human benign and malignant thyroid lesions. Pathol Oncol Res. 2010;16:497–507.PubMedCrossRef
44.
Giaginis C, Michailidi C, Stolakis V, et al. Expression of DNA repair proteins MSH2, MLH1 and MGMT in human benign and malignant thyroid lesions: an immunohistochemical study. Med Sci Monit. 2011;17:BR81–90.PubMed
45.
Giaginis C, Demetriou N, Alexandrou P, et al. Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) expression in human benign and malignant thyroid lesions. Med Sci Monit. 2012;18:BR123–9.PubMed
46.
Karidis NP, Giaginis C, Tsourouflis G, et al. Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: an immunohistochemical study. Med Sci Monit. 2011;17:BR257–65.PubMedCrossRef
47.
Kondo T, Asa SL, Ezzat S. Epigenetic dysregulation in thyroid neoplasia. Endocrinol Metab Clin North Am. 2008;37:389–400.PubMedCrossRef
48.
Russo D, Damante G, Puxeddu E, Durante C, Filetti S. Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol. 2011;46(3):R73–81.PubMedCrossRef
49.
Russo D, Durante C, Bulotta S, Puppin C, Puxeddu E, Filetti S, et al. Targeting histone deacetylase in thyroid cancer. Expert Opin Ther Targets. 2013;17:179–93.PubMedCrossRef
50.
Mitmaker EJ, Griff NJ, Grogan RH, et al. Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors. Surgery. 2011;149:504–11.PubMedCrossRef
51.
Altmann A, Eisenhut M, Bauder-Wüst U. Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275. Eur J Nucl Med Mol Imaging. 2010;37:2286–97.PubMedCrossRef
52.
McKinsey TA, Zhang CL, Olson EN. Identification of a signal responsive nuclear export sequence in class II histone deacetylases. Mol Cell Biol. 2001;21:6312–21.PubMedCentralPubMedCrossRef
53.
Kao HY, Verdel A, Tsai CC, et al. Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7. J Biol Chem. 2001;276:47496–507.PubMedCrossRef
54.
Calalb MB, McKinsey TA, Newkirk S, et al. Increased phosphorylation-dependent nuclear export of class II histone deacetylases in failing human heart. Clin Transl Sci. 2009;2:325–32.PubMedCrossRef
55.
Langley E, Pearson M, Faretta M. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 2002;21:2383–96.PubMedCrossRef
56.
Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet. 2003;19:286–93.PubMedCrossRef
Metadata
Title
Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions
Authors
Constantinos Giaginis
Paraskevi Alexandrou
Ioanna Delladetsima
Ioanna Giannopoulou
Efstratios Patsouris
Stamatios Theocharis
Publication date
01-01-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1007-5

Other articles of this Issue 1/2014

Tumor Biology 1/2014 Go to the issue

Research Article

Significant association between MTHFR C677T polymorphism and hepatocellular carcinoma risk: a meta-analysis

Research Article

Tehranolide inhibits cell proliferation via calmodulin inhibition, PDE, and PKA activation

Research Article

Association of the interleukin-4Rα rs1801275 and rs1805015 polymorphisms with glioma risk

Research Article

Quantitative assessment of the influence of common variations on 6p21 and lung cancer risk

Research Article

XRCC1 R399Q polymorphism and risk of normal tissue injury after radiotherapy in breast cancer patients

Research Article

Deficiency in expression and epigenetic DNA Methylation of ASS1 gene in nasopharyngeal carcinoma: negative prognostic impact and therapeutic relevance
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits